Talk:List of doctors and approaches
May cause a lot more harm than good[edit]
Akiko Iwasaki / vaccination for long haulers[edit]
Key treatment: COVID vaccine
Theory: COVID vaccines seem to help many people suffering from long COVID (but not vaccine injury). It also makes symptoms worse in some long haulers. A viral reservoir of SARS-CoV-2 would explain why vaccination helps with symptoms in those who benefit from vaccination.
Iwasaki is doing a study on long haulers who plan on taking a COVID vaccine. They will receive blood tests that may not be commercially available. Participants must be close to New Haven, CT, USA. https://www.survivorcorps.com/yale
While the results of that study do not seem to be available yet, Iwasaki (@VirusesImmunity) and her colleague Harlan Krumholz are currently enrolling for a study on post-vaccine syndromes (along with long COVID and post-acute infection syndromes). She is certainly recognizing vaccine injury as something that is worth studying.
Iwasaki has various presentations on Youtube such as: https://youtu.be/ggyOnEpM0x8 https://youtu.be/kFqK2M_FK7o
IVIG[edit]
For those patients who did not respond at all, there was no substantial or even minor improvement in symptoms. The distribution of the change in the self-report measures of physical and psychologic morbidity fell in a dichotomous (i.e., almost “all or nothing”) pattern, consistent with the categorized “response” or “no response” assessment from the physician’s interviews.” This is regarding paper (Australia) Lloyd et al., 1990 <ref>Lloyd A., Hickie I., Wakefield D., Boughton C., Dwyer A. A double-blind placebo controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am. J. Med. 1990;89:561–568. doi: 10.1016/0002-9343(90)90173-B</ref>. The notion that either patients substantially improve by responding to treatment, or they saw no improvement at all was replicated in the other 3 studies. This does mean that a significant number of patients across all 4 studies (around 50%) did not see any improvement on wellbeing after IVIG infusion. In terms of clinical suitability, it appears that either patients need to be made aware that clinical efficacy is around 40-50%, or there needs to be more rigorous selection criteria.